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Summary 
Matrix metalloproteinases (MMP) belong to a distinguished class of zinc-depending 
endopeptidases. Zymography is a semi-quantitative tool for determining the activity of 
different MMP isoenzymes in a variety of biological samples. In substrate gel 
zymography, protein samples of different origin (tissue, cell lysates, plasma/serum, 
perfusates, other liquids) are separated in sodium dodecyl sulfate (SDS) 
polyacrylamide gels containing co-polymerized substrate (gelatin, casein, elastin, 
etc.), and after incubation enabling substrate cleavage by MMPs, MMP activities are 
detected after the gel staining as transparent bands against a dark-blue background. 
In situ zymography is a histological modification of substrate zymography in frozen 
sections, allowing detection of the localization of the MMP activities within the tissue. 
Here we describe detailed experimental protocols of all abovementioned techniques 
and provide examples of several sample measurements. 
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 1. Introduction 
1.1 Matrix metalloproteinases in health and disease 
Matrix metalloproteinases (MMPs) are enzymes that belong to the family of zinc-
dependent endopeptidases and are known to play a crucial role in the dynamic 
processing of the extracellular matrix (ECM) facilitating the degradation of matrix 
material. On the other hand, MMPs have been also shown to be present 
intracellularly, thereby influencing physiological as well as pathological intracellular 
signal transduction processes and the contractile machinery. Therefore, MMPs are 
interesting drug targets for several pathologies (see for a review: (1)). The family of 
MMPs include close to 30 members (see for reviews: (2,3)), many of them shown to 
be activated due to different physiological as well as pathological situations in 
different tissues. Some of the important family members together with their 
characteristic features are shown in Table 1. MMPs are synthesized as zymogens 
and can be activated by proteolytic cleavage of an amino-terminal domain, by 
oxidative/nitrosative-induced conformational change (without a change in molecular 
weight), or by phosphorylation (2,4). Activities of MMPs are tightly regulated by their 
endogenous tissue inhibitors (TIMPs) (5). 
TABLE 1 
MMPs play an important role in many physiological and pathological processes, 
including embryogenesis, wound healing, inflammation, cardiovascular diseases and 
tumor development or progression (2,6). Increased activities of different MMPs have 
been reported to be connected with different pathological situations such as 
ischemia-reperfusion injury (7), myocardial contractile dysfunction (8), heart failure 
(9), arthritis (10), neurodegenerative disorders (11), cancer invasion and metastasis 
(12), liver cirrhosis (13), fibrotic lung disease (14), periodontal disease (15) as well as 
with responses to some invasive interventions like anthracycline treatment (16,17) or 
chest irradiation (18) used in the cancer therapy. On the other hand, inhibition of 
MMP activities has been shown to be connected with some kinds of tissue protection 
such as ischemic preconditioning (19,20) or flavonoid-induced cardioprotection (17). 
Moreover, pharmacological inhibition of MMP activities has been shown to be 
cardioprotective in animal models of acute myocardial infarction (21,22) and has also 
been shown to be altered in coronary artery disease patients (23). Being able to 
detect MMPs at early stages of the disease is opening a perspective to use MMPs as 
diagnostic markers. MMPs have been well-investigated in clinical studies of 
cardiovascular diseases: MMP-2 and -9 in Chagas cardiomyopathy (24) and MMP-9 
in ST-segment elevation myocardial infarction (25). Protein expression and activation 
of MMP-2 and MMP-9 has clinical relevance and prognostic value in patients with 
colorectal cancer (26). Fecal MMP-9 is a useful tool for the differential diagnosis of 
diarrheic disorders and in the non-invasive evaluation of disease activity and mucosal 
healing in ulcerative colitis (27). 
Regarding to the abovementioned facts, determination of MMP activities belongs to 
very useful methodologies in biomedical research and is of high clinical importance 
since it seems to be a powerful diagnostic and/or therapeutic tool for the detection or 
follow-up of the abovementioned pathologies. 
1.2  MMP activity detection in biological samples 
 MMP activities can be determined by zymography in different kinds of 
biological samples such as heart, brain, liver, lung tissues, blood vessels or in 
isolated or cultured cell lineages (see Fig. 1-3). Zymography can be performed as a 
substrate zymography, in which the substrate of the certain MMP is incorporated, co-
polymerized in a sodium dodecyl sulfate (SDS) polyacrylamide gel and MMPs are 
separated according to their molecular weights. The activity of MMPs is detected by 
the absence of gelatin in the gel, which can be visualized by transilluminating the gel. 
The activity of the certain MMP is proportional with the intensity and the thickness of 
the corresponding band on zymogram, which can be evaluated electronically by 
using different software after scanning the gels. 
FIG 1 + 2 
 For the detection of MMP activity in situ in different cell or tissue cultures, in 
situ zymography is a suitable method (Fig. 3). In in vivo systems, natural inhibitors of 
MMPs (tissue inhibitors of MMPs, TIMPs) are presented (28). Therefore, when a 
study is designed for detecting MMPs activity in a certain physiological or 
pathological condition, one should calculate not only with the activation, but the 
inhibition of MMPs by TIMPs as well. For this reason, reverse zymography has been 
developed, which allows detection of TIMPs activities in gel zymograms. However, 
this chapter is limited for showing the opportunities to detect MMP activities in 
biological samples, thus here we do not provide detailed description on the available 
techniques for detecting TIMPs activity [for TIMP measurements, see for review (29)]. 
FIG 3 
1.3 Types of zymography substrates 
MMPs cleave different substrates, therefore, the substrate, which is co-polymerized 
in the gel, should be determined according to the MMP isoform.  
Gelatin zymography is predominantly used for measurements of activities of MMP-2 
and MMP-9 as these two MMPs exert strong ability to cleave gelatin as a substrate, 
and are commonly called “gelatinases”. 
In casein zymography, casein is co-polymerized into the polyacrylamide gel as a 
substrate for MMP cleavage. Casein zymography is used for estimation of proteolytic 
activity of MMP-7 due to its ability to cleave casein. 
The most rarely applied type of zymography is elastin zymography, in which soluble 
elastin is co-polymerized in the gel and beside the activity of elastases it can suitably 
show elastinolytic activity for such MMPs, which cleave basically other substrates like 
gelatin (e.g. MMP-2). 
 
2. Materials  
2.1.  Sample preparation 
For pulverized tissue samples 
1. Homogenization buffer: 500 mL double distilled water (ddH2O), 0.335 g (50 mM) 
Tris base, 1 mL (0.5%) Triton X-100. In 500 mL beaker dissolve compounds in 500 
mL ddH2O. Adjust to pH 7.4 with 1 M HCl. Aliquot into 15 mL Falcon tubes. Store at -
20 °C for 1 year. Homogenator: Pellet Pestle Motor, Centrifuge (e.g. Hettich 
Universal 320R), BCA Protein Assay Kit for protein measurement. 
For organ perfusates 
2. Concentrating tubes: Amicon Ultra-4 30 kDa centrifugal filter unit with Ultracel-30 
membrane  for perfusate concentration. 
For cell culture lysates 
3. Phosphate Buffered Saline tablets (PBS): In 200 mL beaker dissolve 1 PBS 
tablet in 100 mL dd H2O Adjust to pH 7.2 with 1 mM NaOH prepare freshly; 
Homogenization buffer (see above step 1); Amicon Ultra 10 kDa concentrating 
tubes. Centrifuge (e.g. Hettich Universal 320R) 
 
2.2. Gelatin zymography 
1 30% Acrylamide / 0.8% Bisacrylamide, Store: at +4 ºC for 1 year. 
2 Separating Gel Solution – 1.5 M Tris HCl, pH 8.8, Store at +4 ºC for 1 year. 
3 2% Gelatin Solution: 100 mg gelatin (type A, from porcine skin; stored at room 
temperature) dissolved in 4.5 mL ddH2O.  
4 10% (w/v) SDS (sodium dodecyl sulfate) solution. Weigh 10 g SDS and dissolve 
in 100 mL ddH2O (Storage: at room temperature for 1 year). 
5 10% (w/v) ammonium persulfate (APS) solution:  Dissolve 100 mg of APS in 1 mL 
ddH2O. Storage: at +4°C for 1 month 
6 TEMED. Storage: at +4 ºC for 1 year. 
7 Stacking Gel Solution: 0.5 M Tris HCl/SDS, pH 6.8. Storage: at +4 °C for 1 year. 
8 ELFO Buffer (25 mM Tris-HCl, 192 mM glycine, 0.1% SDS, pH 8.3). Storage: at 
+4 ºC for 1 year. Or self prepared: 28.83 g glycine, 6.0 g Tris base, 2.0 g SDS. 
Dissolve Tris base and glycine in 1000 mL of ddH2O. Bring solution to 1950 mL 
with ddH2O. Add SDS. Bring solution to 2000 mL total volume with ddH2O. 
Storage: at 4°C for 1 year. 
9 Non-reducing loading (sample) buffers: use commercial “Blue” Zymogram Sample 
Buffer or commercial “Pink” non-reducing lane marker. 
10 For positive control, use “zymography standard”, containing a mixture of purified 
and activated MMP-2 and MMP-9; or MMP-2 standard for gelatin and elastin 
zymography (Fig 1A). For casein zymography, human, recombinant active MMP-7 
can be used. 
11 Renaturation solution: Renaturation buffer (Bio-Rad). Store: at +4 ºC for 1 year. 
Add 1x mL Renaturation buffer (Bio-Rad) + 9x mL ddH2O. Storage: prepare 
freshly. 
12 Development solution: Development buffer (Bio-Rad) Storage: at +4 ºC for 1 year. 
Add 1x mL Development buffer + 9x mL ddH2O. Storage: prepare freshly. 
13 For negative control, use 10 mM ethylene glycol tetraacetic acid (EGTA, binds 
Ca2+ ions, which is obligatory for activity of MMPs). Dissolve 381 mg EGTA in 90 
mL dH2O + 10 mL development buffer. 
14 Coomassie Brilliant Blue (0.05%): 250 mg Coomassie Brilliant Blue G-250, 125 
mL methanol, 50 mL glacial acetic acid, 325 mL ddH2O. Dissolve 250 mg 
Coomassie Brilliant Blue in the mixture of 125 mL methanol and 50 mL glacial 
acetic acid and dilute it by adding 325 mL ddH2O. Storage: at room temperature. 
15 Destaining solution: 40 mL methanol, 80 mL acetic acid, 880 mL ddH2O. Storage: 
at room temperature 
 
2.2.  Casein zymography 
All materials and procedures are identical with gelatin zymography except gelatin 
solution, which is substituted with casein. 
1 Casein solution: 100 mg casein (storage: at room temperature) dissolved in 4.5 
mL phosphate buffer.  
2 Phosphate buffer (126 mM)  
 
2.3.  Elastin zymography 
All materials and procedures are identical with gelatin zymography except gelatin 
solution, which is substituted with elastin. 
Elastin solution: 54 mg soluble elastin from bovine neck ligament dissolved in 4.5 
mL ddH2O. 
2.4.  Materials for in situ zymogrpahy 
EnzCheck Gelatinase/Collagenase Assay Kit (Invitrogen) 
Assay includes the following reagents: 
DQ gelatine from pig skin: five vials (1mg DQ substrate lyophilized from 1 mL of 
PBS in each vial). 
10x Reaction Buffer: 50 mL 
1,10 o-phenanthroline monohydrate: 30mg powder in a vial. 
Collagenase type IV. from Clostridium Histolyticum: 500U collagenase powder in 
a vial. 
 
3. Methods 
3.1.  Sample preparation 
Pulverized tissue sample 
1. Weigh out 30-50 mg heart (lung, pancreas, aorta, spleen) tissue powder into a 
liquid-nitrogen-frozen 1.5 mL Eppendorf tube. Avoid thawing. It can be stored 
at -80 ºC for 2 years. 
2. Thaw an appropriate amount of homogenization buffer (see Note 1). 
3. Add 4× volume homogenization buffer to the sample (e.g. 30 mg sample and 
120 µL buffer). 
4. Homogenize the mixture by Pellet Pestle Motor for 3×10 sec (see Note 2) 
5. Centrifuge the homogenate at 4 ºC for 10 min at 10000 g, and collect the 
supernatant, and store at -80 ºC for maximum 1 month. 
6. Measure protein concentration by a BCA kit. Usually 20× dilution of tissue 
homogenates is required. 
Preparing perfusate samples 
1. In case of perfusate sample, use Amicon Ultra 30 kDa concentrating tubes to 
concentrate 4×3 mL perfusate sample to 50-100 µl.  
2. Pour 3 mL perfusate in the concentrating insert of an Amicon tube. 
3. Put concentrating insert into the tube and close it. Spin samples at 7500 × g 
for 20 min, 4 °C. 
4. Remove the concentrating insert and discard the flow through from the tube. 
Reinsert the concentrating insert. 
5. Pour 3 mL perfusate in the insert, recap and spin it for 20 min. Repeat steps 3-
4 twice more. 
6. Pipette out the concentrated sample from the insert into an Eppendorf tube. 
7. Measure protein concentration by BCA kit. Usually 3× dilution of perfusate 
concentrates is required. 
Cell culture lysates 
1. For cell culturing see ref. (30) (culturing neonatal cardiac myocytes)  
2. Remove treating solutions and wash cells in 2 mL PBS two times, then remove 
PBS. 
3. Scrape cells from 2 wells of a 6-well plate in 200 µL zymography 
homogenization buffer (2 wells together are 400 µL and they are collected into 
1 tube after washing both wells). In case of 25 cm2 flask use 400 µL buffer, in 
case of 75 cm2 flask, use 1 mL buffer. 
4. Keep Eppendorf tubes with the suspensions on ice and take into -80°C freezer 
or concentrate them freshly. 
3.2 Concentration of samples  
1. Keep samples on ice. 
2. Homogenize the mixture by ultrasonic homogenizer 2× 5 sec on ice. 
3. Centrifuge cell homogenates at 5000 × g for 10 min at 4°C. 
4. Collect supernatant. 
5. Centrifuge the supernatant in Amicon Ultra 10 kDa concentrating tubes to 
increase the sample protein concentration (4000 × g for 30-50 min at -4°C)  
6. Put 50-100 µL samples into -80 °C freezer in 2 aliquots (1 aliquot for 
determination of protein concentration). 
7. Measure protein concentration by BCA kit. Usually 3× dilution of cell 
concentrates is required. 
 
3.3.  Preparation of separating gel  
1. Preparation of substrate for electrophoresis 
a) gelatin solution 
Add 100 mg gelatin to 4.5 mL ddH2O. 
Gently heat and mix solution until it dissolves (beaker will be warm to touch, 
max. 40°C). If it has cooled down, add 0.5 mL 10% (w/v) SDS aqueous 
solution to reach final desired volume and concentration. Prepare freshly. 
(Note 3) 
b) casein solution 
Dissolve 100 mg casein in 4.5 mL phosphate buffer.  
Stir until casein dissolves.  
Preparation of phosphate buffer: mix 7.12 g Na2HPO4 dissolved in 400 mL 
ddH2O and 1.56 g NaH2PO4 dissolved in 100 mL ddH2O, set at pH 7.4. 
Add 0.5 mL 10% w/v SDS aqueous solution to reach final desired volume. 
OR 
Dissolve 30 mg casein in 2 mL of 75 mM Tris HCl, pH = 8.8 
c) elastin solution 
Add 54 mg κ-elastin to 4.5 mL H2O  
Stir until elastin dissolves.  
Add 0.5 mL 10% w/v SDS aqueous solution to reach final desired volume. 
2. Assemble electrophoresis unit. (Note 4)  
3. Mark desired level of separating gel on unit (use comb). 
4. Mix 30% acrylamide/0.8% bisacrylamide solution with Tris HCl, pH 8.8, gelatin 
solution and ddH2O (Table 2). 
5. Add 10% APS solution and TEMED to the mix quickly (Table 2) 
6. Swirl to get homogenous gel. Avoid bubbling. Use immediately as 
polymerization process has begun. (Note 5) 
7. Using a pipette, pour a small amount into sandwich plates and watch for 
leakage. In the absence of leakage, continue filling up to 1 mm above line. 
8. Gently add butanol (with a 27G-needle connected to a 10-mL syringe) along 
top to remove bubbles. (Note 6)  
9. Allow gels to polymerize (approximately 20 min at 25 °C). Use this time to 
prepare stacking gel (without adding TEMED and 10% APS) (Note 7)  
10. A layer of H2O on top of the gel will be visible when polymerization is 
complete. Drain this layer from the unit with a small stripe of blotting paper. 
 
3.3.  Preparation of stacking gel  
1. Mix 30% acrylamide/0.8% bisacrylamide solution with Tris HCl, pH 6.8 and 
ddH2O (Table 3). 
2. Add 10% SDS, 10% APS and TEMED quickly (Table 3). 
3. Swirl to mix. Avoid bubbling. Use immediately as polymerization process has 
begun. 
4. Place comb in units and then use pipettes to pour stacking gel. 
5. Allow gels to polymerize (approximately 15 min at 25 °C). Use this time to 
make sample calculation. 
 
3.4.  Sample calculation 
1. According to the results of protein measurement, sample loading mass and 
volume should be calculated. 
2. From a tissue homogenate, 50 µg protein per lane should be loaded. Since we 
load 15 µl per lane, this means that the final protein concentration of sample 
needs to be 50 µg/15 µl. 
3. In case you want to load a sample only once, it is enough to prepare 2× 
volume of one load (30 µl), which means that we should add 6 µl (1/5 part) 
“pink” or 20 µl (2/3 part) “blue” loading buffer. 
4. The remaining 24 µl or 10 µl, respectively, should contain 2×50 µg = 100 µg 
protein. Therefore, volume of the sample will be: V1=100 µg/protein 
concentration of your sample. 
5. Then we should add ddH2O to dilute samples. The required volume of ddH2O 
is: V2 = 30-V1. 
Taken together: 
Loading volume:  15 µl 
Loaded protein:  50 µg 
Prepared volume:  30 µl (2× Loading volume) 
Prepared (sample) mass: 2× Loaded protein (100 µg) 
“Pink” loading buffer: 1/5 of prepared volume (6 µl) OR 
“Blue” loading buffer: 2/3 of prepared volume (20 µl) 
Sample volume: V1= 2× loaded protein (2× 50 µg)/sample protein 
concentration (µg/µL) 
ddH2O:   V2=Prepared volume (30 µl)-V1  
 
3.5.  Sample loading and running gels 
1. Prepare and cool down ELFO buffer: 50 mL ELFO + 450 mL ddH2O (avoid 
bubbles, mix gently, cool down). (Note 10) 
2. Mark gel lanes for sample loading. Do not use the two outside lanes. 
3. When gel is polymerized, remove combs by pulling straight up.  
4. Remove gel plates and snap onto electrode assembly. (Note 11) 
5. Fill up the lower and the upper buffer container with tank buffer. 
6. In case of casein zymography: pre-run electrophoresis at 40mV for 15 min at 
4°C before the samples are loaded into the wells. Another possibility is to load 
sample buffer into one well and pre-run electrophoresis at 4°C until it reaches 
the bottom of the gel. Afterwards continue with step 7, but keep gels at 4°C. 
(Note 12). 
7. Load samples 
For identification of different isoforms of detected MMPs, positive controls (e.g. 
zymography standard containing human MMP-2 and -9 or MMP-2 standard.) 
should be used. Page ruler is also useful to detect the different size of bands. 
Leave one lane loaded with sample for negative control (see in section 3.6). 
8. Connect electrodes properly (red to red, black to black) and set voltage at 90 
V. 
9. For 8% gel run till dye gets until the bottom of gel. (Note 13) 
10. Use this time to prepare renaturation solution and development buffer. 
3.6.  Washing and incubating gels 
1. Set dry incubator at 37 °C. 
2. Disassemble gel apparatus.  
3. Cut down lane for negative control. (Note 14) 
4. Wash gels for 40 min in 200 mL Renaturation solution at room temperature. 
(Note 15, 16) 
5. Wash gels for 20 min 200 mL Development buffer. (Note 15, 16) 
6. Place gels in fresh 200 mL development buffer. (Note 16) For negative 
control, incubate lane separately in 10 mM EGTA solution. 
7. Incubate gels into dry incubator at 37 oC for 20-40 h. (Even before staining, 
gelatinolytic activity should be visible, if not, longer incubation should be 
applied). (Note 17) 
3.7.  Staining gels and preparation for evaluation of MMP activity 
1. Even before staining, gelatinolytic activity should be visible (hold the gel up 
against a dark background to visualize). 
2. Put gels in Coomassie Brilliant Blue solution. Place on a shaker for 1 h. (Note 
18) 
3. Put gels in destaining solution. Place on shaker (at least 40 min). (Note 19, 
20) 
4. Gelatinolytic activities should be detected as transparent bands against the 
blue background of Coomassie Brilliant Blue stained gelatin (see Figures 1-3). 
5. Scan the gel in transparent mode with a special gel scanner. 
6. Evaluate MMPs activity by using a gel/film evaluation software (e.g. Quantity 
one, Bio-Rad) 
3.8 In situ zymography 
The present description provides details for performing in situ zymography for MMP-2 
in cardiac myocytes (Fig. 3), however, techniques for showing other MMP activities in 
different tissue sections or cell cultures in situ are also existing and a description for 
general in situ zymographies is available in ref. (31). 
 
1. Culture neonatal rat cardiac myocytes (30) or other cell types in 24-well tissue 
culture plate at the density of 105 cells/well for 3 days. 
2. Replace the growth medium (DMEM supplemented with Glu, AB/AM, 1%FBS) with 
a “stress” solution containing DQ substrate at 40 μg/mL concentration. In case of 
control group, replace the medium of the cells with a control solution containing 
DQ substrate at the abovementioned concentration. 
3. Subject cells to circumstances according to your aim/project, which may induce 
intracellular MMP-2 activation. 
4. For negative control samples, use ilomastat (at 0.5 µM final concentration), or 
other non-specific MMP inhibitor (e.g. 1,10-o-pheanthroline at 1-5 mM final 
concentration, SB-3CT at 1-10 nM final concentration). 
5. Subsequently, replace “stress” solution with growth medium containing DQ 
substrate at 40 μg/mL concentration (250ul volume must be applied onto the 
cells). 
6. Replace the medium, and wash cells twice with D-PBS. 
7. Rinse cells in 3.7% PFA in PBS at room temperature for 15 min. 
8. Wash cells twice with PBS. 
9. Rinse coverslips with mounting medium and view fluorescent signal under 
fluorescent microscope. 
10. If it is necessary you can combine in situ zymography with immunocytochemistry. 
In this case after the fixation you should continue with an appropriate 
immunostaining protocol. 
 
4. Notes 
1 Avoid reducing agents (e.g. dithiothreitol; DTT) or protease inhibitors (e.g.  
phenylmethanesulfonyl fluoride; PMSF) in the homogenization buffer. They may 
reduce or inhibit MMP activities, thereby may lead to false results. 
2 Avoid ultrasonic homogenator. It can destroy the native structure of MMPs, 
therefore enzymes lost their activities. 
3 Gelatin is very sensible. Make sure that gelatin dissolves completely (clear, 
transparent solution without any opalescent particle). By cooling avoid gel 
formation (too long cooling). When SDS is added, avoid precipitation. If gelatin 
precipitates, try to heat again. If precipitates will not disappear from the solution, 
make a new gelatin solution. Precipitated gelatin does not polymerize 
homogenously in the gel and leads irrelevant results in the enzyme activity. 
4 In order to avoid leakage, ensure that spacers, comb and glass plates are aligned 
properly. 
5 Make sure that gel is horizontal and there is no difference in the levels of the two 
edges. 
6 Avoid “shooting” the butanol, and butanol covers the hole top surface of the gel 
uniformly. 
7 TIP: leave pipette tip in the left over separating gel, when it is polymerized you will 
be able to lift it with the pipette. 
8 Mix 15.0 mL of separating gel. This volume is sufficient for 1 small unit (contains 
10 lanes) (i.e. 2 gels), or for 1 triple-wide unit (contains 30-33 lanes) mix 22.5 mL. 
9 7.5-10% polyacrylamide gels are recommended for gelatin zymography. For 
casein zymography, we recommend to use 10-15% gels according to the MW of 
active MMP-7 (19-21kDa; 28-30 kDa pro-MMP-7). 
10 Calculate the necessary volume of ELFO buffer according the used buffer tank. 
11 Eliminate bubbles under the gel, they may disturb gel running. 
12 Casein migrates in gel during electrophoresis. Due to its low molecular weight (23 
kDa) the zone containing casein can obscure MMP-7 (latent form - 29 kDa, active 
form - 20 kDa) after staining. Therefore pre-run of casein-embedded gel is 
recommended before classical zymogram procedure in order to get excess of 
casein out of the gel. The amount of remaining casein is sufficient for detection of 
MMP activities (32). 
13 Average time for gel running: 1.5-2 hours. 
14 Avoid gel rupture. Cut the different corner of the gels to be able to identify the gels 
later (e.g. cut the bottom left corner of gel #1, and both the top and bottom left 
corners for gel #2. (Ensure that the gel is oriented correctly so that you don’t 
accidentally cut the right side corner) 
15 Before preparation of Renaturation and Development buffer, make sure, that the 
buffers do not contain any visible contamination (e.g. fungal particles). Buffers 
should be clear and transparent. 
16 Make sure that gels immerse in the buffers and are not attached to the wall of the 
dish. 
17 20-hour incubation is recommended for lung samples, 40-hour for heart samples. 
Individual differences may occur, therefore the authors recommend to run a pilot 
zymography for set up incubation time. 
18 Staining can be longer, if it is necessary. The gel should be dark blue. 
19 Use clear dish and change destaining solution after a couple of minutes (5-10 
min), if it becomes bluish. 
20 Leave the gel in destaining solution until the stacking gel become completely 
destained (transparent) again (Fig .1 and 3). It can last even for 12 hours. 
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Figure legends 
 
Figure 1: Representative gelatin zymograms performed from human samples. Panel 
A: Human serum samples from patients with coronary artery disease. Some of the 
patients have increased MMP-2 and/or MMP-9 activity as indicated by the 
zymographic intensity at 72 or 86 kDa, respectively. Panel B: Gelatin zymogram from 
human isolated lymphocytes. 72 kDa-MMP-2 activity is markedly visible, however, 
other activities at 64 (MMP-2) and at 86 kDa (MMP-9) can also be observed. Weak 
gelatinolytic activity signals can be seen in both panels at 192 kDa, which may 
indicate the dimerized form of MMP-9 (33) (Roomi et al., 2014). 
 
Figure 2: Representative gelatin zymograms performed from homogenates of murine 
tissues (L1-4: lanes 1-4; 15 µg protein was loaded into each wells). Panel A 
represents mouse heart homogenates, which expresses mainly the 72-kDa isoform 
of MMP-2. Weak signal for MMP-9 can be observed, however, it indicates 
inappropriate removal of blood from heart samples. Panel B: lung samples from mice 
subjected to chronic tobacco smoking (L2 and 4) and their controls (L1 and 3). A 
markedly increased intensity can be observed at 92 kDa (MMP-9). Panel C: Samples 
derived from the aorta of transgenic mice. L1-2: ApoB100LDL-/- mice, control and 
Chlamydia pneumoniae (Cpn) infected; L3-4: ApoE-/-, control and Cpn infected. 
 
Figure 3: Examples of MMP zymography y in isolated and/or cultured cells. Panel A: 
gelatin zymogram from cultured neonatal cardiac myocytes after resuspension. 
Gelatinolytic activities can be detected at completely different molecular weights than 
that of heart homogenates (for comparison see Fig 2A). Panel B and C: In situ gelatin 
zymography in fixed neonatal cardiac myocyte culture in normoxic conditions (Panel 
B) and subjected to simulated ischemia/reoxygeation (Panel C). Panel C shows an 
increased gelatinolytic activity (represented as green fluorescence - DQ™ fluorescent 
gelatin; red fluorescence: MMP-2 immunostaining by rhodamine-labeled goat anti-
mouse antibody, blue fluorescence: cell nuclei by Hoechst 33342 staining) in cardiac 
myocytes, which indicates the presence and activation of MMP-2 during simulated 
ischemic stress. Scale bars = 20 µm. 
Table 1: The family of MMPs and their characteristic features.  
MMP 
codes 
Alternative 
names 
Molecular 
weight (kDa)  Substrates Pathologies 
Z* A* 
MMP-1 interstitial collagenase 57 52 gelatin 
atherosclerosis, melanoma, heart 
failure 
MMP-2 gelatinase A, type IV collagenase 75/72 64 gelatin, elastin 
myocardial infarction, heart failure, 
gastritis, rheumatoid arthritis 
MMP-3 stromelysin-1 57 45 gelatin, elastin, casein brain injury, neurodegeneration 
MMP-7 matrilysin 28 19 gelatin, elastin, casein 
tumor-induced osteolysis, colon 
cancer 
MMP-8 neutrophil collagenase 75 57 gelatin coronary artery disease, angina 
MMP-9 gelatinase B 92 86 gelatin, elastin myocarditis and subsequent dilated cardiomyopathy, ulcerative colitis 
MMP-10 stromelysin-2 57 44 gelatin, elastin, casein lung cancer 
MMP-11 stromelysin-3 51 44 gelatin, elastin, casein 
tumor progression, breast 
carcinomas 
MMP-12 macrophage metalloelastase 54 22 
gelatin, 
elastin, casein 
granulomatous skin diseases, 
inflammatory disorders 
MMP-13 collagenase-3 65 48 gelatin breast carcinomas 
MMP-14 MT1-MMP 66 54 gelatin, casein tumor growth by activating MMP-2 
MMP-15 MT2-MMP 76 N/A fibronectin. laminin 
obesity, pre-eclampsia, ovarian 
carcinoma 
MMP-16 MT3-MMP 64 52/30 gelatin, casein breast cancer 
MMP-17 MT4-MMP 71 67 N/A pre-eclampsia 
MMP-19 RASI-1 57 N/A gelatin rheumatoid arthritis 
MMP-20 enamelysin 54 42.5  amelogenesis imperfecta 
MMP-21 N/A N/A N/A N/A melanoma, ovarian and colon carcinomas 
MMP-22 N/A N/A 42 N/A N/A 
MMP-23 N/A N/A N/A N/A breast cancer 
MMP-24 MT5-MMP N/A N/A N/A brain tumors 
MMP-25 MT6-MMP, leucolysin 56 38 pro-MMP-2 inflammatory hyperalgesia 
MMP-26 endometase 29 19 gelatin lung cancer 
*Z and A indicates the zymogen or active form(s) of MMPs, respectively. 
 
Table 2: Preparation of separating gel between 0.75-1.5 mm thickness (Note 8, 9) 
STOCK SOLUTIONS 
Final acrylamide concentration in the separating 
gel (%) 
7.0 7.5 8.0 9.0 10.0 
small gel 
(15 mL) 
large gel 
(22.5 mL) 
30% acrylamide / 0.8% bisacrylamide 
(mL) 
3.5 3.75 4.0 6 4.5 5.0 
1.5 M Tris-HCl, pH 8.8 (mL) 3.75 3.75 3.75 5.62 3.75 3.75 
ddH2O (mL) 6.25 6.0 5.75 8.62 5.25 4.75 
Gelatin/casein/elastin solution 
(20/20/12 mg/mL, 1 % w/v SDS; mL) 
1.5 1.5 1.5 2.25 1.5 1.5 
10% w/v Ammonium Persulfate 
Solution (APS; µL) 
50 50 10 75 50 50 
TEMED (µL) 10 10 10 15 10 10 
 
 Table 3: Preparation of 5 mL stacking gel. 
STOCK SOLUTIONS VOLUME 
30% acrylamide/ 0.8% bisacrylamide  1 mL 
0.5 M Tris HCl pH 6.8 1.25 mL 
ddH2O 3.05 mL 
10% SDS 50 µL 
10% w/v Ammonium Persulfate Solution (APS) 25 µL 
TEMED 8 µL 
 
